Weight loss treatments do more than reduce weight, they subtly alter body composition, raising new scientific questions about their full impact.
New obesity treatments may be changing more than the number on the scale. Vanderbilt Health researchers found that both newer weight loss drugs and bariatric (weight loss) surgery improve body composition by sharply reducing fat mass while causing a smaller decline in fat-free mass, which includes lean muscle.
This matters because not all weight loss is biologically equal. Excess fat mass (FM) is tied to a higher risk of obesity-related death, including serious cardiovascular events. Fat-free mass (FFM), by contrast, plays a protective role and is closely linked to strength, physical function, and overall resilience.
In findings published in JAMA Network Open, the researchers said more work is needed to understand how these changes play out in real-world care after bariatric surgery or treatment with current GLP-1 receptor agonist drugs. The study was led by Danxia Yu, PhD, associate professor of Medicine in the Division of Epidemiology, and Jason Samuels, MD, assistant professor of Surgery.
Patient Data and Methodology
To explore that question, the team reviewed electronic health records from 3,066 adults treated at Vanderbilt University Medical Center. The study included 1,257 patients ages 18 to 65 who had bariatric surgery between 2017 and 2022, along with 1,809 patients who were treated with semaglutide or tirzepatide between 2018 and 2023. Patients with a history of end-stage kidney disease or congestive heart failure were excluded.
Researchers tracked changes in body composition using bioelectrical impedance analysis, a practical clinical method that estimates fat mass (FM) and fat-free mass (FFM) from factors such as height, weight, age, race, gender, diabetes history, and GLP-1 treatment duration. It is not the most precise tool available, but it allows doctors to follow body composition over time in large groups of patients.
